Original Research
Published on 16 Jul 2018
Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2018.01614
- 11,581 views
- 28 citations


